News NEJM responds to claims of bias from Justice Department The New England Journal of Medicine (NEJM) has hit back at assertions of bias in its editorial policies from Republican activist Edward Martin Jr.
News Eisai's full lecanemab phase 3 trial results for Alzheimer's... Following the news of two lecanemab-related deaths reported on the eve of the C
News Mixed results for experimental Alzheimer's therapies at CTAD The CTAD Alzheimer's meeting hears encouraging data for new drug candidates from the likes of Biogen, AriBio, and BMS - but also some disappointments.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.